Latvija -
latviešu -
Zāļu valsts aģentūra
lamictal 100 mg košļājamās/disperģējamās tabletes
glaxosmithkline trading services limited, ireland - lamotrigīns - košļājamā/disperģējamā tablete - 100 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
lamictal 100 mg košļājamās/disperģējamās tabletes
glaxosmithkline s.p.a., italy - lamotrigīns - košļājamā/disperģējamā tablete - 100 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
methotrexat-ebewe 5 mg tabletes
ebewe pharma ges.m.b.h nfg.kg, austria - metotreksāts - tablete - 5 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
lamotrigine accord 5 mg košļājamās/disperģējamās tabletes
accord healthcare b.v., netherlands - lamotrigīns - košļājamā/disperģējamā tablete - 5 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
lamotrigine accord 25 mg košļājamās/disperģējamās tabletes
accord healthcare b.v., netherlands - lamotrigīns - košļājamā/disperģējamā tablete - 25 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
lamotrigine accord 100 mg košļājamās/disperģējamās tabletes
accord healthcare b.v., netherlands - lamotrigīns - košļājamā/disperģējamā tablete - 100 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
methotrexat-ebewe 5 mg tabletes
ebewe pharma ges.m.b.h nfg.kg, austria - metotreksāts - tablete - 5 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
methotrexat-ebewe 5 mg tabletes
ebewe pharma ges.m.b.h nfg.kg, austria - metotreksāts - tablete - 5 mg
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiski līdzekļi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.